Shimada Ken

Researcher

基本情報

Profile and Settings

• 氏名

  Shimada Ken

Affiliation

• Medical Oncology, Professor

Location

• Koto Toyosu Hospital

Degree

• Doctor of Medical Science, Showa University, Nov. 1996

Achievements

Published Papers

• Association Between ABCC2 -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer., Nakayama Hana;Ishida Hiroo;Iidaka Masanori;Kato Shoko;Nakatani Kei;Nakayama Akihiro;Noguchi Toshihiro;Nishihara Shigetoshi;Oikawa Shu;Usami Tomono;Mitsui Yuta;Ishii Y U;Toshima Hirokazu;Kobayashi Kouji;Murase Remi;Matsumoto Natsumi;Suzuki Kosuke;Shimada Ken;Yoshida Hitoshi;Fujita Ken-Ichi, Anticancer research, 44(11), 2024, Peer-reviewed
• A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer, Yukitaka Shibata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Ken-Ichi Fujita, Cancer Chemother Pharmacol, Aug. 2023, Peer-reviewed, DOI:doi.org/10.1007/s00280-023-04584-x
• High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., OHKUMA Ryotaro;YADA Erica;ISHIKAWA Shumpei;KOMURA Daisuke;ISHIZAKI Hidenobu;TAMADA Koji;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;ONOUE Rie;ANDO Kiyohiro;TSURUTANI Junji;YOSHIMURA Kiyoshi;YOKOBORI Takehiko;SASADA Tetsuro;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;IZUMIZAKI Masahiko;KOBAYASHI Shinichi;TSUNODA Takuya;WADA Satoshi, PloS One, 15(1):e0226707, Jan. 2020, Peer-reviewed

Presentations

• A polymorphism in ABCC3 is associated with capecitabine-induced hand-foot syndrome and capecitabine pharmacokinetics, Kengo Omata, Natsumi Matsumoto, Remi Murase, Yutaro Kubota, Hiroo Ishida3 Ken Shimada, and Ken-ichi Fujita, 2025 the Japanese Society of Medical Oncology Annual Meeting, 06 Mar. 2025
• Association between ABCC2 -24C>T and nab-paclitaxel-induced peripheral neuropathy in Japanese patients with pancreatic cancer, Hana Nakayama,Hiroo Ishida, Masanori Iidaka, Shoko Kato, Kei Nakatani, Akihiro Nakayama, Toshihiro Noguchi, Shigetoshi Nishihara, Shu Oikawa, Tomono Usami, Yuta Mitsui, Yu Ishii, Hirokazu Toshima, Kouji Kobayashi, Remi Murase, Natsumi Matsumoto, Kosuke Suzuki, Ken Shimada, Hitoshi Yoshida, Ken-ichi Fujita, 2025 the Japanese Society Medical Oncology annual Meeting, 06 Mar. 2025, 日本臨床腫瘍学会, 神戸
• Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
• Reduced systemic exposure to a capecitabine metabolite 5'-DFUR in ABCC4 polymorphism may be associated with increases in cAMP level and subsequent upregulation of thymidine phosphorylase, Natsumi Matsumoto, Ayano Oishi, Yutaro Kubota, Hiroo Ishida, Ken Shimada, Yusuke Masuo, Yukio Kato, Ken-ichi Fujita, ASCPT 2024 Annual Meeting, 28 Mar. 2024, American Society for Clinical Pharmacology & Therapeutics, Colorado Springs, United States
• A polymorphisms in ABCA2 is associated with pharmacokinetics and toxicity of capecitabine in colorectal cancer patients, Yukitaka Shibata, Natsumi Matsumoto, Yutaro Kubota, Takuya Tsunoda, Hiroo Ishida, Ken Shimada, Ken-ichi Fujita, The 20th Japanese Society of Medical Oncology annual meeting, 16 Mar. 2023, fukuoka